UDCA Dosage and Administration Guidelines

Introduction to UDCA Therapy

The American Association for the Study of Liver Diseases recommends against UDCA as medical therapy for adult Primary Sclerosing Cholangitis (PSC) patients, with a Grade 1A recommendation 2
The British Society of Gastroenterology provides a STRONG recommendation against routine UDCA use in newly diagnosed PSC 5, 6

The established first-line treatment for PBC is UDCA at 13-15 mg/kg/day, which should be administered as a single bedtime dose, according to the American College of Gastroenterology 3, 4
This dosage significantly decreases serum bilirubin, alkaline phosphatase, cholesterol, and immunoglobulin M levels compared to placebo, as recommended by the American Association for the Study of Liver Diseases 3
Long-term treatment at this dose delays histological progression when started at early disease stages, as suggested by the European Association for the Study of the Liver 3
Treatment is associated with significant reduction in likelihood of liver transplantation or death in patients with moderate to severe PBC, according to the American College of Gastroenterology 3

Low-dose UDCA (10-15 mg/kg/day) improves liver biochemistry but does not improve clinical outcomes including death, transplantation, or disease progression, as reported by the European Association for the Study of the Liver 5, 6
Moderate-dose UDCA (15-20 mg/kg/day) may be considered in select cases as it can improve serum liver tests and surrogate markers of prognosis, though available data does not support a firm recommendation, according to the American Association for the Study of Liver Diseases 1, 3
High-dose UDCA (28-30 mg/kg/day) MUST BE AVOIDED due to association with increased serious adverse events, higher rates of death, liver transplantation, and development of varices, as warned by the American College of Gastroenterology 1, 5, 6

The recommended dosage is 10-15 mg/kg/day divided into 2-3 doses daily, as suggested by the American College of Obstetricians and Gynecologists 3
Decrease in pruritus typically occurs within 1-2 weeks, and biochemical improvement is usually seen within 3-4 weeks, according to the Society for Maternal-Fetal Medicine 3
If pruritus is not relieved, the dose can be titrated to a maximum of 21 mg/kg/day, as recommended by the American College of Gastroenterology 3
UDCA is considered safe during pregnancy and breastfeeding, according to the American Academy of Pediatrics 3

Single bedtime dosing of the full daily dose is recommended for PBC, according to the American College of Gastroenterology 4
Long-term therapy is generally required for chronic liver diseases, as suggested by the European Association for the Study of the Liver 7
Regular monitoring of liver biochemistry is essential to assess treatment response, according to the American Association for the Study of Liver Diseases 3
Biochemical response should be evaluated after 1 year of therapy to identify patients at risk of progressive disease, as recommended by the American College of Gastroenterology 3